CriticalMagnesium salt: intravenous solution and oral saline laxative×Class Ia antiarrhythmic (sodium channel blocker with intermediate kinetics)
Updated · Methodology
Mechanism
According to the Spanish magnesium sulfate summaries of product characteristics (SmPCs), magnesium sulfate given with quinidine derivatives can raise plasma quinidine concentrations to the point of overdose risk, because alkalinisation of the urine reduces renal elimination of quinidine (magnesium sulfate SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.5). According to the US quinidine label, about 20% of a quinidine dose appears unchanged in the urine when the urine pH is below 7, but this fraction drops to as little as 5% when the urine is more alkaline. Drugs that alkalinise the urine reduce renal elimination of quinidine (quinidine label, US Food and Drug Administration, FDA, Clinical Pharmacology and Drug Interactions). Quinidine prolongs the QT interval, which can lead to torsade de pointes. The risk is higher with high serum quinidine levels, a slow heart rate, or low potassium, magnesium or calcium (FDA quinidine label, Warnings).
Symptoms
The documents do not describe how this particular combination presents. The magnesium sulfate SmPCs name a rise in quinidine concentration and a risk of overdose as its consequence (magnesium sulfate summaries of product characteristics, SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.5). In quinidine overdose, the main dangers are ventricular arrhythmias and low blood pressure. Vomiting, diarrhoea, tinnitus, high-frequency hearing loss, vertigo, blurred vision, double vision, photophobia, headache, confusion and delirium can also occur (quinidine label, US Food and Drug Administration, FDA, Overdosage). QT prolongation caused by quinidine can lead to torsade de pointes, a life-threatening ventricular arrhythmia. Frequent extrasystoles, ventricular tachycardia, ventricular flutter and ventricular fibrillation have also been reported with quinidine (FDA quinidine label, Warnings).
Management
The combination is contraindicated: the Spanish summaries of product characteristics (SmPCs) for injectable magnesium sulfate, both the original product and the generic, list use with quinidine derivatives as a contraindication (magnesium sulfate SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.3). The US quinidine label does not mention magnesium, but it states that drugs that alkalinise the urine reduce renal elimination of quinidine. Interactions that change quinidine levels can lead to toxicity or loss of effect if the quinidine dose is not adjusted (quinidine label, US Food and Drug Administration, FDA, Drug Interactions and Warnings). If the two drugs have nevertheless been given together, the US quinidine label notes that QT prolongation can be monitored as a guide to safety and may give better guidance than serum quinidine levels (FDA quinidine label, Clinical Pharmacology). For haemodynamically unstable polymorphic ventricular tachycardia, including torsade de pointes, stop quinidine and perform immediate cardioversion or, if a pacemaker is in place or immediately available, immediate overdrive pacing (FDA quinidine label, Overdosage). The same label says to look for factors contributing to QT prolongation, especially low potassium, magnesium and calcium, and to correct them aggressively if possible, but it does not say how (FDA quinidine label, Overdosage). During intravenous magnesium sulfate infusion, monitor blood pressure and serum magnesium. Stop the infusion if blood pressure falls or the heart rate slows, if serum magnesium exceeds 2.5 mmol/L or if the knee-jerk reflex disappears (magnesium sulfate SmPC, AEMPS, section 4.4).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Quinidine Sulfate Tablets USP (quinidine sulfate) prescribing information (2023)– FDA, DailyMed setid b0d6341b-d880-4f0b-8844-bc788c03004a (Epic Pharma), revisión 11/2023, secciones Clinical Pharmacology, Warnings, Precautions (Drug Interactions) y Overdosage
- AEMPS: Ficha técnica: Sulfato de magnesio, Sulmetin Simple 150 mg/ml solución inyectable y para perfusión (nº registro 23622), sección 4.3 (2025)– AEMPS, CIMA, nº registro 23622 (Sulmetin Simple 150 mg/ml solución inyectable y para perfusión, Desma Laboratorio Farmacéutico), revisión 02/2025, secciones 4.3, 4.4 y 4.5
- AEMPS: Ficha técnica: Sulfato de magnesio Altan 150 mg/ml solución inyectable y para perfusión EFG (nº registro 78350), sección 4.3 (2021)– AEMPS, CIMA, nº registro 78350 (Altan Pharmaceuticals), revisión 11/2021, secciones 4.3 y 4.5